Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

NCT00509093 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: imatinib mesylate
GENETIC: gene expression analysis
GENETIC: mutation analysis
GENETIC: polymerase chain reaction
OTHER: flow cytometry
PROCEDURE: biopsy

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]